PMID- 28413872
OWN - NLM
STAT- MEDLINE
DCOM- 20170428
LR  - 20221207
IS  - 2185-2243 (Electronic)
IS  - 0385-0005 (Linking)
VI  - 42
IP  - 1
DP  - 2017 Apr 20
TI  - Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 
      Diabetes after Switching from Insulin Therapy to Liraglutide, a Human 
      Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-.
PG  - 52-57
AB  - OBJECTIVE: Hemodialysis patients are advised to limit the intake of foods in 
      order to control volume status and body weight (BW). We report the clinical 
      course of five Japanese hemodialysis patients with type 2 diabetes mellitus 
      (T2DM) who were switched from insulin to liraglutide, and the efficacy of the 
      treatment, especially in terms of changes in interdialysis weight gain (IDWG). 
      METHODS: This retrospective pilot study included 5 Japanese hemodialysis patients 
      with T2DM. Insulin and other oral hypoglycemic agents, if any, were discontinued 
      before switching to liraglutide. The initial dose of liraglutide was set at 0.3 
      mg/day for more than 1 week, increased to 0.6 mg/day for more than 1 week and 
      then, to 0.9 mg/day if needed. RESULTS: At baseline, the mean body mass index 
      (BMI) was 23.2 +/- 1.2 kg/m(2) and mean IDWG was 2.0 +/- 0.4 kg. The required dose of 
      liraglutide ranged from 0.3 to 0.9 mg/day. At the end of 3-month treatment, 
      liraglutide reduced HbA1c level, BMI, and IDWG. A significant decrease in 
      cardiothoracic ratio was confirmed on chest radiography. CONCLUSION: Switching 
      from insulin to liraglutide seems effective in hemodialysis patients with T2DM, 
      especially in those with difficult blood fluid volume control associated with 
      failure of dietary restriction.
FAU - Kondo, Masumi
AU  - Kondo M
FAU - Toyoda, Masao
AU  - Toyoda M
AD  - Division of Nephrology and Metabolism,Department of Internal Medicine, Tokai 
      University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, 
      Japan. m-toyoda@is.icc.u-tokai.ac.jp.
FAU - Kimura, Moritsugu
AU  - Kimura M
FAU - Ishida, Naoto
AU  - Ishida N
FAU - Fukagawa, Masafumi
AU  - Fukagawa M
LA  - eng
PT  - Journal Article
DEP - 20170420
PL  - Japan
TA  - Tokai J Exp Clin Med
JT  - The Tokai journal of experimental and clinical medicine
JID - 7704186
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Aged
MH  - *Blood Volume
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/*physiopathology/*therapy
MH  - Diet
MH  - *Drug Substitution
MH  - Female
MH  - Glucagon-Like Peptide 1/*analogs & derivatives
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Insulin/therapeutic use
MH  - Japan
MH  - Liraglutide/*administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - *Renal Dialysis
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Weight Gain
EDAT- 2017/04/18 06:00
MHDA- 2017/04/30 06:00
CRDT- 2017/04/18 06:00
PHST- 2016/07/12 00:00 [received]
PHST- 2017/02/09 00:00 [accepted]
PHST- 2017/04/18 06:00 [entrez]
PHST- 2017/04/18 06:00 [pubmed]
PHST- 2017/04/30 06:00 [medline]
PST - epublish
SO  - Tokai J Exp Clin Med. 2017 Apr 20;42(1):52-57.